A detailed history of Janus Henderson Group PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,175,641 shares of CPRX stock, worth $51 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,175,641
Previous 2,726,388 20.2%
Holding current value
$51 Million
Previous $43.5 Million 22.45%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $8.08 Million - $9.32 Million
-550,747 Reduced 20.2%
2,175,641 $33.7 Million
Q1 2024

May 15, 2024

BUY
$13.18 - $17.11 $20.9 Million - $27.2 Million
1,587,794 Added 139.45%
2,726,388 $43.5 Million
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $8.61 Million - $12.6 Million
730,695 Added 179.14%
1,138,594 $19.1 Million
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $1.19 Million - $1.52 Million
101,392 Added 33.08%
407,899 $4.77 Million
Q2 2023

Aug 14, 2023

BUY
$11.5 - $18.08 $3.03 Million - $4.76 Million
263,116 Added 606.38%
306,507 $4.12 Million
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $335,197 - $492,043
23,375 Added 116.78%
43,391 $719,000
Q4 2022

Feb 14, 2023

SELL
$12.25 - $19.5 $12 - $19
-1 Reduced -0.0%
20,016 $372,000
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $306,735 - $674,297
-43,447 Reduced 68.46%
20,017 $257,000
Q2 2022

Aug 15, 2022

SELL
$6.23 - $8.57 $376,017 - $517,250
-60,356 Reduced 48.74%
63,464 $445,000
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $179,090 - $280,271
-33,727 Reduced 21.41%
123,820 $1.03 Million
Q4 2021

Feb 14, 2022

BUY
$5.21 - $7.45 $74,289 - $106,229
14,259 Added 9.95%
157,547 $1.07 Million
Q3 2021

Nov 16, 2021

SELL
$4.85 - $6.04 $129,858 - $161,721
-26,775 Reduced 15.74%
143,288 $759,000
Q2 2021

Aug 16, 2021

BUY
$4.29 - $6.05 $729,570 - $1.03 Million
170,063 New
170,063 $978,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.41B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.